Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UMBRIEL Phase IIb Tozorakimab in Uncontrolled Asthma (Japan)
jRCT2031250046Phase 2Recruiting
- Sponsor
- AstraZeneca
- Start
- Apr 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, double-blind trial of tozorakimab in asthma (3 arms), sponsored by AstraZeneca. Primary endpoint: Annualised rate of severe asthma exacerbations. Started Apr 2025; status: recruiting.
02
Drugs
tozorakimab
03
Conditions
asthma
Beyond the preview
Go deeper on jRCT2031250046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250046.